{"id":703022,"date":"2026-02-11T13:22:21","date_gmt":"2026-02-11T18:22:21","guid":{"rendered":"https:\/\/www.kff.org\/?p=703022"},"modified":"2026-02-11T13:22:23","modified_gmt":"2026-02-11T18:22:23","slug":"the-ira-has-improved-coverage-of-drugs-selected-for-medicare-price-negotiation","status":"publish","type":"post","link":"https:\/\/www.kff.org\/medicare\/the-ira-has-improved-coverage-of-drugs-selected-for-medicare-price-negotiation\/","title":{"rendered":"The IRA Has Improved Coverage of Drugs Selected for Medicare Price Negotiation"},"content":{"rendered":"<div\n\tclass=\"wp-block-kff-shared-content--standard-layout wp-block-kff-shared-content\">\n\t\n\n<section class=\"wp-block-kff-shared-content-main\">\n\t\t\t<div class=\"post-header\">\n\t\t\t\t\t\n\t<h1 class=\"post-header__title\">The IRA Has Improved Coverage of Drugs Selected for Medicare Price Negotiation<\/h1>\n\n\t\n\t\t\t<div class=\"post-header__meta\">\n\t\t\t\t\t<div>\n\t\t\t\t<span class=\"post-header__meta-label\">\n\t\t\t\tAuthors:\t\t\t\t<\/span>\n\t\t\t\t<a href=\"https:\/\/www.kff.org\/person\/juliette-cubanski\/\">Juliette Cubanski<\/a> and <a href=\"https:\/\/www.kff.org\/person\/nolan-sroczynski\/\">Nolan Sroczynski<\/a> \t\t\t<\/div>\n\t\t\t\t<div>\n\t\t\t<span class=\"post-header__meta-label\">Published:<\/span>\n\t\t\t<date>Feb 11, 2026<\/date>\n\t\t<\/div>\n\t\t<\/div>\n\t\n\t<div class=\"post-header__social-sharing\">\n\t\t<button class=\"post-header__social-sharing__button print\">\n\t\t\t<svg width=\"16\" height=\"17\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n\t\t\t\t<path d=\"M4.348 2.5v3.391H2.783A.787.787 0 0 0 2 6.674v4.696c0 .429.353.782.783.782h1.565V14.5h7.304v-2.348h1.565c.43 0 .783-.353.783-.782V6.674a.787.787 0 0 0-.783-.783h-1.565V2.5H4.348Zm.522.522h6.26v2.87H4.87v-2.87ZM2.783 6.413h1.782a.26.26 0 0 0 .085 0h6.697a.26.26 0 0 0 .086 0h1.784c.148 0 .261.114.261.26v4.697c0 .147-.113.26-.26.26h-1.566V9.283H4.348v2.347H2.783a.257.257 0 0 1-.261-.26V6.674c0-.147.113-.261.26-.261Zm9.39.783a.522.522 0 1 0 0 1.043.522.522 0 0 0 0-1.043ZM4.87 9.804h6.26v2.043a.264.264 0 0 0 0 .086v2.045H4.87v-2.043a.261.261 0 0 0 0-.085V9.804Zm1.043.783a.262.262 0 0 0-.265.26.26.26 0 0 0 .265.262h4.174a.26.26 0 1 0 0-.522H5.913Zm0 1.043a.26.26 0 1 0 0 .522h3.13a.26.26 0 1 0 0-.522h-3.13Zm0 1.044a.26.26 0 1 0 0 .522h4.174a.262.262 0 0 0 .264-.261.26.26 0 0 0-.264-.261H5.913Z\" fill=\"#004B88\" stroke=\"#004B88\" stroke-width=\".5\"\/>\n\t\t\t<\/svg>\n\n\t\t\tPrint\t\t<\/button>\n\t\t<a href=\"mailto:?subject=The%20IRA%20Has%20Improved%20Coverage%20of%20Drugs%20Selected%20for%20Medicare%20Price%20Negotiation&#038;body=https%3A%2F%2Fwww.kff.org%2Fmedicare%2Fthe-ira-has-improved-coverage-of-drugs-selected-for-medicare-price-negotiation%2F\" class=\"post-header__social-sharing__button\">\n\t\t\t<svg width=\"16\" height=\"17\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n\t\t\t\t<path d=\"M2.333 4.25h-.25v9.14h12.5V4.25H2.333Zm1.083 1.693-.353-.2V5.23h10.54v.513l-.353.2L8.333 8.73 3.416 5.943Zm-.353 6.467V6.884l.107.06 5.04 2.857.123.07.123-.07 5.04-2.857.107-.06v5.526H3.063Z\" fill=\"#004B88\" stroke=\"#004B88\" stroke-width=\".5\"\/>\n\t\t\t<\/svg>\n\n\t\t\tEmail\t\t<\/a>\n\t\t<button class=\"post-header__social-sharing__button copy\">\n\t\t\t<svg width=\"16\" height=\"17\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n\t\t\t\t<path d=\"M11.533 2.9c-.615 0-1.23.235-1.697.702L8.502 4.936a2.4 2.4 0 0 0-.575 2.46l.958-.958a1.32 1.32 0 0 1 .371-.748l1.334-1.333a1.331 1.331 0 0 1 1.886 0c.52.52.52 1.365 0 1.885l-1.334 1.333c-.21.21-.474.331-.748.372l-.958.958a2.393 2.393 0 0 0 2.46-.576l1.334-1.333a2.402 2.402 0 0 0 0-3.394 2.393 2.393 0 0 0-1.697-.702Zm-1.61 3.46a.533.533 0 0 0-.367.162l-3.2 3.2a.533.533 0 1 0 .754.754l3.2-3.2a.534.534 0 0 0-.387-.915ZM6.586 7.973a2.388 2.388 0 0 0-1.816.697l-1.334 1.333a2.403 2.403 0 0 0 0 3.394 2.393 2.393 0 0 0 1.697.702c.614 0 1.229-.234 1.697-.702l1.333-1.334a2.4 2.4 0 0 0 .576-2.46l-.959.958a1.32 1.32 0 0 1-.37.749l-1.334 1.333a1.334 1.334 0 0 1-1.886-1.885l1.334-1.334c.21-.21.474-.331.748-.372l.958-.957c-.21-.07-.426-.11-.644-.122Z\" fill=\"#004B88\"\/>\n\t\t\t<\/svg>\n\n\t\t\t<span>Copy Link<\/span>\n\t\t<\/button>\n\t\t\t<\/div>\n\t<\/div>\n\t\t\t\n\n<p class=\"wp-block-paragraph\">The <a href=\"https:\/\/www.kff.org\/medicare\/faqs-about-the-inflation-reduction-acts-medicare-drug-price-negotiation-program\/\">Medicare Drug Price Negotiation Program<\/a>, enacted as part of the <a href=\"https:\/\/www.congress.gov\/bill\/117th-congress\/house-bill\/5376\">Inflation Reduction Act of 2022<\/a> (IRA), was designed to help lower Medicare spending on prescription drugs by requiring the federal government to negotiate the price of some high-cost drugs covered by Medicare. Along with lowering prices, the negotiation program could also improve coverage of drugs selected for negotiation for Medicare beneficiaries because the <a href=\"https:\/\/www.congress.gov\/bill\/117th-congress\/house-bill\/5376\/text#:~:text=(I)%20Required%20inclusion%20of%20selected%20drugs.\">law requires<\/a> all Medicare Part D plans to cover each of the selected drugs, including all dosages and forms, when negotiated prices take effect.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">To measure the effect of the IRA\u2019s coverage requirement for selected drugs, this analysis examines 2026 Medicare Part D formulary coverage of drugs selected for negotiation, including the <a href=\"https:\/\/www.cms.gov\/files\/document\/fact-sheet-negotiated-prices-initial-price-applicability-year-2026.pdf\">first 10 drugs<\/a> selected for price negotiation that now have Medicare-negotiated prices available as of January 1, 2026, and the second set of <a href=\"https:\/\/www.cms.gov\/files\/document\/factsheet-medicare-negotiation-selected-drug-list-ipay-2027.pdf\">15 drugs selected<\/a> for price negotiation, whose <a href=\"https:\/\/www.cms.gov\/files\/document\/fact-sheet-negotiated-prices-ipay-2027.pdf\">negotiated prices<\/a> will take effect in 2027. The analysis shows that for several dosages and forms of nine out of the first 10 selected drugs, coverage rates have improved since 2025, before the IRA\u2019s coverage requirement took effect.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-the-ira-s-coverage-requirement-for-selected-drugs-led-to-improved-coverage-of-the-part-d-drugs-with-negotiated-prices-available-in-2026\">The IRA\u2019s coverage requirement for selected drugs led to improved coverage of the Part D drugs with negotiated prices available in 2026<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Consistent with the IRA\u2019s coverage requirement, in 2026, all Part D enrollees have coverage of all 10 selected drugs with negotiated prices available this year, including all dosage forms and strengths. Moreover, access to several doses and forms of 9 of the first 10 drugs selected for negotiation has improved since 2025 (Figure 1). In particular, coverage rates of the insulin products Fiasp and NovoLog and two dosages of the cancer drug Imbruvica have expanded the most. Fiasp was covered for 24% of Part D enrollees in 2025, while NovoLog was covered for 32%, and two dosages of Imbruvica were covered for roughly half Part D enrollees in 2025.<\/p>\n\n\n\n<div class=\"datawrapper-embed block--datawrapper-embed \">\n\t\t\t\t\t<div style=\"min-height: px;\">\n\t\t\t<script\n\t\t\t\ttype=\"text\/javascript\"\n\t\t\t\tdefer\n\t\t\t\tsrc=\"https:\/\/datawrapper.dwcdn.net\/3HAfW\/embed.js?v=14\"\n\t\t\t>\n\t\t\t<\/script>\n\t\t<\/div>\n\t\t\t<img\n\t\t\tclass=\"datawrapper-embed__print-img\"\n\t\t\tsrc=\"https:\/\/datawrapper.dwcdn.net\/3HAfW\/full.png\"\n\t\t\talt=\"The IRA\u2019s Coverage Requirement for Selected Drugs Led to Improved Coverage of the Medicare Part D Drugs with Negotiated Prices Available in 2026\"\n\t\t\/>\n<\/div>\n\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-the-ira-s-coverage-requirement-will-improve-coverage-of-several-of-the-15-selected-drugs-with-negotiated-prices-available-in-2027-including-the-glp-1-drug-wegovy\">The IRA\u2019s coverage requirement will improve coverage of several of the 15 selected drugs with negotiated prices available in 2027, including the GLP-1 drug Wegovy<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The GLP-1 drug, Wegovy, one of the 15 selected drugs with negotiated prices available in 2027, is currently covered by a small number of Part D plans enrolling less than 1% of Part D enrollees in 2026 (Figure 2). Wegovy is approved for both obesity and cardiovascular disease risk reduction but Medicare Part D plans are currently allowed to cover Wegovy <a href=\"https:\/\/www.kff.org\/medicare\/a-new-use-for-wegovy-opens-the-door-to-medicare-coverage-for-millions-of-people-with-obesity\/\">only for cardiovascular disease<\/a> because Medicare is prohibited from covering drugs used for weight loss. The Trump administration is planning to launch a <a href=\"https:\/\/www.cms.gov\/priorities\/innovation\/innovation-models\/balance\">temporary, voluntary model<\/a> to expand Medicare coverage of GLP-1s to treat obesity beginning in 2027, which would allow beneficiaries in participating Part D plans to use Wegovy for this purpose.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The IRA\u2019s Part D coverage requirement for selected drugs will increase the share of Part D enrollees who have coverage of Wegovy for Medicare-covered uses beginning in 2027, along with 6 other selected drugs for 2027 that are not currently covered for all Part D enrollees, including Austedo and Austedo XR, a treatment for involuntary movement disorders (covered for 72% and 51% of enrollees, respectively); Otezla, a treatment for psoriasis and psoriatic arthritis (covered for 68% of enrollees); and Breo Ellipta, a treatment for asthma and COPD (covered for 74% of enrollees). At the same time, several of these drugs are already covered for all or nearly all Part D enrollees, including six drugs that belong to one of the <a href=\"https:\/\/www.cms.gov\/newsroom\/fact-sheets\/medicare-advantage-and-part-d-drug-pricing-final-rule-cms-4180-f\">six protected classes of drugs<\/a> that are required to be covered by all plans: Xtandi, Pomalyst, Ofev, Ibrance, and Calquence are antineoplastics (drugs used to treat cancer) and Vraylar is an antipsychotic.<\/p>\n\n\n\n<div class=\"datawrapper-embed block--datawrapper-embed \">\n\t\t\t\t\t<div style=\"min-height: px;\">\n\t\t\t<script\n\t\t\t\ttype=\"text\/javascript\"\n\t\t\t\tdefer\n\t\t\t\tsrc=\"https:\/\/datawrapper.dwcdn.net\/DRDsY\/embed.js?v=14\"\n\t\t\t>\n\t\t\t<\/script>\n\t\t<\/div>\n\t\t\t<img\n\t\t\tclass=\"datawrapper-embed__print-img\"\n\t\t\tsrc=\"https:\/\/datawrapper.dwcdn.net\/DRDsY\/full.png\"\n\t\t\talt=\"The IRA&#039;s Coverage Requirement for Selected Drugs Will Improve Access to the GLP-1 Drug Wegovy and Six Other Part D Drugs Selected for Negotiation in Round 2, Starting in 2027\"\n\t\t\/>\n<\/div>\n\n\n\n\n<div class=\"is-style-blue-box wp-block-tenup-callout\">\n\t\n\t\t\t<div class=\"wp-block-tenup-callout__content\">\n\t\t\t\n\n<p class=\"wp-block-paragraph\">This work was supported in part by Arnold Ventures. KFF maintains full editorial control over all of its policy analysis, polling, and journalism activities.<\/p>\n\n\t\t<\/div>\n\t\n\t<\/div>\n\n\t<div class=\"post-footer\">\n\t<div class=\"post-footer__title\">More On<\/div>\n\t<div class=\"post-footer__links\">\n\t\t\t\t\t\t\t\t<a href=\"https:\/\/www.kff.org\/topic\/medicare\/\">\n\t\t\t\tMedicare\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<a href=\"https:\/\/www.kff.org\/tag\/benefits\/\">\n\t\t\t\tBenefits\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<a href=\"https:\/\/www.kff.org\/tag\/coverage\/\">\n\t\t\t\tCoverage\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<a href=\"https:\/\/www.kff.org\/tag\/medicare-part-d\/\">\n\t\t\t\tMedicare Part D\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<a href=\"https:\/\/www.kff.org\/tag\/obesity\/\">\n\t\t\t\tObesity\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<a href=\"https:\/\/www.kff.org\/tag\/prescription-drugs\/\">\n\t\t\t\tPrescription Drugs\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<a href=\"https:\/\/www.kff.org\/tag\/seniors\/\">\n\t\t\t\tSeniors\t\t\t<\/a>\n\t\t\t<\/div>\n<\/div>\n\t<\/section>\n\n\n<section class=\"wp-block-kff-shared-content-sidebar\">\n\t\t\t\n\t\t\n<div class=\"wp-block-kff-shared-related-content--green wp-block-kff-shared-related-content\">\n\t<h2 class=\"wp-block-kff-shared-related-content__heading\">Related Content<\/h2>\n\t<div>\n\t\t\t<div class=\"wp-block-kff-shared-related-content__card\">\n\t\t\t<a href=\"https:\/\/www.kff.org\/medicare\/the-effect-of-delaying-the-selection-of-small-molecule-drugs-for-medicare-drug-price-negotiation\/\" class=\"wp-block-kff-shared-related-content__link\">\n\t\t\t\t<h3 class=\"wp-block-kff-shared-related-content__card-title\">\n\t\t\t\t\tThe Effect of Delaying the Selection of Small Molecule Drugs for Medicare Drug Price Negotiation\t\t\t\t<\/h3>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/div>\n\t\t\t<div class=\"wp-block-kff-shared-related-content__card\">\n\t\t\t<a href=\"https:\/\/www.kff.org\/medicare\/recent-trends-in-glp-1-use-and-spending-in-medicare\/\" class=\"wp-block-kff-shared-related-content__link\">\n\t\t\t\t<h3 class=\"wp-block-kff-shared-related-content__card-title\">\n\t\t\t\t\tRecent Trends in GLP-1 Use and Spending in Medicare\t\t\t\t<\/h3>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/div>\n\t\t\t<div class=\"wp-block-kff-shared-related-content__card\">\n\t\t\t<a href=\"https:\/\/www.kff.org\/medicare\/faqs-about-the-inflation-reduction-acts-medicare-drug-price-negotiation-program\/\" class=\"wp-block-kff-shared-related-content__link\">\n\t\t\t\t<h3 class=\"wp-block-kff-shared-related-content__card-title\">\n\t\t\t\t\tFAQs about the Inflation Reduction Act\u2019s Medicare Drug Price Negotiation Program\t\t\t\t<\/h3>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\t\t\t<\/section>\n\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>The Medicare drug price negotiation program could improve coverage of drugs selected for negotiation for Medicare beneficiaries because the law requires all Medicare Part D plans to cover each of the selected drugs, including all dosages and forms, when negotiated prices take effect.<br \/>\nThis analysis examines 2026 Medicare Part D formulary coverage of drugs selected for negotiation to measure the effect of the IRA&#8217;s coverage requirement. <\/p>\n","protected":false},"author":48717755,"featured_media":703065,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"authors":[{"type":"foundation","id":67181,"name":"","_id":"2cf1ca48-4b9e-4bb4-89b7-a8ab99731943"},{"type":"foundation","id":528717,"name":"","_id":"3a4e93d0-8e2d-4b2d-87e3-5b8a850c9466"}],"exhibits":[],"jetpack_post_was_ever_published":false,"ep_exclude_from_search":false,"_classifai_error":"","_classifai_text_to_speech_error":"","hide_from_search":false,"show_featured_image":false,"subheading":"","tag":"","search_keywords":"10944","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"shortlink":"","footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[69737],"tags":[82404,128562,38834,5705,69739,43427],"content-types":[579145483],"series":[],"program":[155109811],"partner":[],"class_list":["post-703022","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicare","tag-benefits","tag-coverage","tag-medicare-part-d","tag-obesity","tag-prescription-drugs","tag-seniors","content-types-issue-brief","program-program-on-medicare-policy"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.9 (Yoast SEO v25.9) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>The IRA Has Improved Coverage of Drugs Selected for Medicare Price Negotiation | KFF<\/title>\n<meta name=\"description\" content=\"The Medicare drug price negotiation program could improve coverage of drugs selected for negotiation for Medicare beneficiaries because the law requires all Medicare Part D plans to cover each of the selected drugs, including all dosages and forms, when negotiated prices take effect.\nThis analysis examines 2026 Medicare Part D formulary coverage of drugs selected for negotiation to measure the effect of the IRA&#039;s coverage requirement.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.kff.org\/medicare\/the-ira-has-improved-coverage-of-drugs-selected-for-medicare-price-negotiation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The IRA Has Improved Coverage of Drugs Selected for Medicare Price Negotiation | KFF\" \/>\n<meta property=\"og:description\" content=\"The Medicare drug price negotiation program could improve coverage of drugs selected for negotiation for Medicare beneficiaries because the law requires all Medicare Part D plans to cover each of the selected drugs, including all dosages and forms, when negotiated prices take effect. This analysis examines 2026 Medicare Part D formulary coverage of drugs selected for negotiation to measure the effect of the IRA&#039;s coverage requirement.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.kff.org\/medicare\/the-ira-has-improved-coverage-of-drugs-selected-for-medicare-price-negotiation\/\" \/>\n<meta property=\"og:site_name\" content=\"KFF\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-11T18:22:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-11T18:22:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2026\/02\/The-IRA-Coverage-Requirement-for-Selected-Drugs-Will-Improve-Access-to-the-GLP-1-Drug-Wegovy-and-Six-Other-Part-D-Drugs-Selected-for-Negotiation-in-Round-2-Starting-in-2027_FI.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1600\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"kffjuliettec\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"kffjuliettec\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.kff.org\/medicare\/the-ira-has-improved-coverage-of-drugs-selected-for-medicare-price-negotiation\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.kff.org\/medicare\/the-ira-has-improved-coverage-of-drugs-selected-for-medicare-price-negotiation\/\"},\"author\":[{\"@id\":\"https:\/\/www.kff.org\/#\/schema\/person\/41b7d5d5453c18736d78ffb01d45ee51\"},{\"@id\":\"https:\/\/www.kff.org\/#\/schema\/person\/e6a548c2c2596d8d63277db7af714bab\"}],\"headline\":\"The IRA Has Improved Coverage of Drugs Selected for Medicare Price Negotiation\",\"datePublished\":\"2026-02-11T18:22:21+00:00\",\"dateModified\":\"2026-02-11T18:22:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.kff.org\/medicare\/the-ira-has-improved-coverage-of-drugs-selected-for-medicare-price-negotiation\/\"},\"wordCount\":614,\"publisher\":{\"@id\":\"https:\/\/www.kff.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.kff.org\/medicare\/the-ira-has-improved-coverage-of-drugs-selected-for-medicare-price-negotiation\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2026\/02\/The-IRA-Coverage-Requirement-for-Selected-Drugs-Will-Improve-Access-to-the-GLP-1-Drug-Wegovy-and-Six-Other-Part-D-Drugs-Selected-for-Negotiation-in-Round-2-Starting-in-2027_FI.png\",\"keywords\":[\"Benefits\",\"Coverage\",\"Medicare Part D\",\"Obesity\",\"Prescription Drugs\",\"Seniors\"],\"articleSection\":[\"Medicare\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.kff.org\/medicare\/the-ira-has-improved-coverage-of-drugs-selected-for-medicare-price-negotiation\/\",\"url\":\"https:\/\/www.kff.org\/medicare\/the-ira-has-improved-coverage-of-drugs-selected-for-medicare-price-negotiation\/\",\"name\":\"The IRA Has Improved Coverage of Drugs Selected for Medicare Price Negotiation | KFF\",\"isPartOf\":{\"@id\":\"https:\/\/www.kff.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.kff.org\/medicare\/the-ira-has-improved-coverage-of-drugs-selected-for-medicare-price-negotiation\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.kff.org\/medicare\/the-ira-has-improved-coverage-of-drugs-selected-for-medicare-price-negotiation\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2026\/02\/The-IRA-Coverage-Requirement-for-Selected-Drugs-Will-Improve-Access-to-the-GLP-1-Drug-Wegovy-and-Six-Other-Part-D-Drugs-Selected-for-Negotiation-in-Round-2-Starting-in-2027_FI.png\",\"datePublished\":\"2026-02-11T18:22:21+00:00\",\"dateModified\":\"2026-02-11T18:22:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.kff.org\/medicare\/the-ira-has-improved-coverage-of-drugs-selected-for-medicare-price-negotiation\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.kff.org\/medicare\/the-ira-has-improved-coverage-of-drugs-selected-for-medicare-price-negotiation\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.kff.org\/medicare\/the-ira-has-improved-coverage-of-drugs-selected-for-medicare-price-negotiation\/#primaryimage\",\"url\":\"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2026\/02\/The-IRA-Coverage-Requirement-for-Selected-Drugs-Will-Improve-Access-to-the-GLP-1-Drug-Wegovy-and-Six-Other-Part-D-Drugs-Selected-for-Negotiation-in-Round-2-Starting-in-2027_FI.png\",\"contentUrl\":\"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2026\/02\/The-IRA-Coverage-Requirement-for-Selected-Drugs-Will-Improve-Access-to-the-GLP-1-Drug-Wegovy-and-Six-Other-Part-D-Drugs-Selected-for-Negotiation-in-Round-2-Starting-in-2027_FI.png\",\"width\":1600,\"height\":900},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.kff.org\/#website\",\"url\":\"https:\/\/www.kff.org\/\",\"name\":\"KFF - The independent source for health policy research, polling, and news\",\"description\":\"The independent source for health policy research, polling, and news\",\"publisher\":{\"@id\":\"https:\/\/www.kff.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.kff.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.kff.org\/#organization\",\"name\":\"KFF\",\"url\":\"https:\/\/www.kff.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.kff.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2025\/04\/KFF_Black.png\",\"contentUrl\":\"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2025\/04\/KFF_Black.png\",\"width\":3186,\"height\":1296,\"caption\":\"KFF\"},\"image\":{\"@id\":\"https:\/\/www.kff.org\/#\/schema\/logo\/image\/\"}},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.kff.org\/medicare\/the-ira-has-improved-coverage-of-drugs-selected-for-medicare-price-negotiation\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.kff.org\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The IRA Has Improved Coverage of Drugs Selected for Medicare Price Negotiation\",\"item\":\"https:\/\/www.kff.org\/medicare\/the-ira-has-improved-coverage-of-drugs-selected-for-medicare-price-negotiation\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"The IRA Has Improved Coverage of Drugs Selected for Medicare Price Negotiation\"}]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.kff.org\/#\/schema\/person\/41b7d5d5453c18736d78ffb01d45ee51\",\"name\":\"Juliette Cubanski\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.kff.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2013\/04\/Cubanski-Juliette.jpg?w=300\",\"contentUrl\":\"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2013\/04\/Cubanski-Juliette.jpg?w=300\",\"caption\":\"Juliette Cubanski\"},\"url\":\"https:\/\/www.kff.org\/person\/juliette-cubanski\/\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.kff.org\/#\/schema\/person\/e6a548c2c2596d8d63277db7af714bab\",\"name\":\"Nolan Sroczynski\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.kff.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2022\/12\/Sroczynski-Nolan.jpg?w=300\",\"contentUrl\":\"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2022\/12\/Sroczynski-Nolan.jpg?w=300\",\"caption\":\"Nolan Sroczynski\"},\"url\":\"https:\/\/www.kff.org\/person\/nolan-sroczynski\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"The IRA Has Improved Coverage of Drugs Selected for Medicare Price Negotiation | KFF","description":"The Medicare drug price negotiation program could improve coverage of drugs selected for negotiation for Medicare beneficiaries because the law requires all Medicare Part D plans to cover each of the selected drugs, including all dosages and forms, when negotiated prices take effect.\nThis analysis examines 2026 Medicare Part D formulary coverage of drugs selected for negotiation to measure the effect of the IRA's coverage requirement.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.kff.org\/medicare\/the-ira-has-improved-coverage-of-drugs-selected-for-medicare-price-negotiation\/","og_locale":"en_US","og_type":"article","og_title":"The IRA Has Improved Coverage of Drugs Selected for Medicare Price Negotiation | KFF","og_description":"The Medicare drug price negotiation program could improve coverage of drugs selected for negotiation for Medicare beneficiaries because the law requires all Medicare Part D plans to cover each of the selected drugs, including all dosages and forms, when negotiated prices take effect. This analysis examines 2026 Medicare Part D formulary coverage of drugs selected for negotiation to measure the effect of the IRA's coverage requirement.","og_url":"https:\/\/www.kff.org\/medicare\/the-ira-has-improved-coverage-of-drugs-selected-for-medicare-price-negotiation\/","og_site_name":"KFF","article_published_time":"2026-02-11T18:22:21+00:00","article_modified_time":"2026-02-11T18:22:23+00:00","og_image":[{"width":1600,"height":900,"url":"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2026\/02\/The-IRA-Coverage-Requirement-for-Selected-Drugs-Will-Improve-Access-to-the-GLP-1-Drug-Wegovy-and-Six-Other-Part-D-Drugs-Selected-for-Negotiation-in-Round-2-Starting-in-2027_FI.png","type":"image\/png"}],"author":"kffjuliettec","twitter_card":"summary_large_image","twitter_misc":{"Written by":"kffjuliettec","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.kff.org\/medicare\/the-ira-has-improved-coverage-of-drugs-selected-for-medicare-price-negotiation\/#article","isPartOf":{"@id":"https:\/\/www.kff.org\/medicare\/the-ira-has-improved-coverage-of-drugs-selected-for-medicare-price-negotiation\/"},"author":[{"@id":"https:\/\/www.kff.org\/#\/schema\/person\/41b7d5d5453c18736d78ffb01d45ee51"},{"@id":"https:\/\/www.kff.org\/#\/schema\/person\/e6a548c2c2596d8d63277db7af714bab"}],"headline":"The IRA Has Improved Coverage of Drugs Selected for Medicare Price Negotiation","datePublished":"2026-02-11T18:22:21+00:00","dateModified":"2026-02-11T18:22:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.kff.org\/medicare\/the-ira-has-improved-coverage-of-drugs-selected-for-medicare-price-negotiation\/"},"wordCount":614,"publisher":{"@id":"https:\/\/www.kff.org\/#organization"},"image":{"@id":"https:\/\/www.kff.org\/medicare\/the-ira-has-improved-coverage-of-drugs-selected-for-medicare-price-negotiation\/#primaryimage"},"thumbnailUrl":"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2026\/02\/The-IRA-Coverage-Requirement-for-Selected-Drugs-Will-Improve-Access-to-the-GLP-1-Drug-Wegovy-and-Six-Other-Part-D-Drugs-Selected-for-Negotiation-in-Round-2-Starting-in-2027_FI.png","keywords":["Benefits","Coverage","Medicare Part D","Obesity","Prescription Drugs","Seniors"],"articleSection":["Medicare"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.kff.org\/medicare\/the-ira-has-improved-coverage-of-drugs-selected-for-medicare-price-negotiation\/","url":"https:\/\/www.kff.org\/medicare\/the-ira-has-improved-coverage-of-drugs-selected-for-medicare-price-negotiation\/","name":"The IRA Has Improved Coverage of Drugs Selected for Medicare Price Negotiation | KFF","isPartOf":{"@id":"https:\/\/www.kff.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.kff.org\/medicare\/the-ira-has-improved-coverage-of-drugs-selected-for-medicare-price-negotiation\/#primaryimage"},"image":{"@id":"https:\/\/www.kff.org\/medicare\/the-ira-has-improved-coverage-of-drugs-selected-for-medicare-price-negotiation\/#primaryimage"},"thumbnailUrl":"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2026\/02\/The-IRA-Coverage-Requirement-for-Selected-Drugs-Will-Improve-Access-to-the-GLP-1-Drug-Wegovy-and-Six-Other-Part-D-Drugs-Selected-for-Negotiation-in-Round-2-Starting-in-2027_FI.png","datePublished":"2026-02-11T18:22:21+00:00","dateModified":"2026-02-11T18:22:23+00:00","breadcrumb":{"@id":"https:\/\/www.kff.org\/medicare\/the-ira-has-improved-coverage-of-drugs-selected-for-medicare-price-negotiation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.kff.org\/medicare\/the-ira-has-improved-coverage-of-drugs-selected-for-medicare-price-negotiation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.kff.org\/medicare\/the-ira-has-improved-coverage-of-drugs-selected-for-medicare-price-negotiation\/#primaryimage","url":"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2026\/02\/The-IRA-Coverage-Requirement-for-Selected-Drugs-Will-Improve-Access-to-the-GLP-1-Drug-Wegovy-and-Six-Other-Part-D-Drugs-Selected-for-Negotiation-in-Round-2-Starting-in-2027_FI.png","contentUrl":"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2026\/02\/The-IRA-Coverage-Requirement-for-Selected-Drugs-Will-Improve-Access-to-the-GLP-1-Drug-Wegovy-and-Six-Other-Part-D-Drugs-Selected-for-Negotiation-in-Round-2-Starting-in-2027_FI.png","width":1600,"height":900},{"@type":"WebSite","@id":"https:\/\/www.kff.org\/#website","url":"https:\/\/www.kff.org\/","name":"KFF - The independent source for health policy research, polling, and news","description":"The independent source for health policy research, polling, and news","publisher":{"@id":"https:\/\/www.kff.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.kff.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.kff.org\/#organization","name":"KFF","url":"https:\/\/www.kff.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.kff.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2025\/04\/KFF_Black.png","contentUrl":"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2025\/04\/KFF_Black.png","width":3186,"height":1296,"caption":"KFF"},"image":{"@id":"https:\/\/www.kff.org\/#\/schema\/logo\/image\/"}},{"@type":"BreadcrumbList","@id":"https:\/\/www.kff.org\/medicare\/the-ira-has-improved-coverage-of-drugs-selected-for-medicare-price-negotiation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.kff.org"},{"@type":"ListItem","position":2,"name":"The IRA Has Improved Coverage of Drugs Selected for Medicare Price Negotiation","item":"https:\/\/www.kff.org\/medicare\/the-ira-has-improved-coverage-of-drugs-selected-for-medicare-price-negotiation\/"},{"@type":"ListItem","position":3,"name":"The IRA Has Improved Coverage of Drugs Selected for Medicare Price Negotiation"}]},{"@type":"Person","@id":"https:\/\/www.kff.org\/#\/schema\/person\/41b7d5d5453c18736d78ffb01d45ee51","name":"Juliette Cubanski","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.kff.org\/#\/schema\/person\/image\/","url":"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2013\/04\/Cubanski-Juliette.jpg?w=300","contentUrl":"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2013\/04\/Cubanski-Juliette.jpg?w=300","caption":"Juliette Cubanski"},"url":"https:\/\/www.kff.org\/person\/juliette-cubanski\/"},{"@type":"Person","@id":"https:\/\/www.kff.org\/#\/schema\/person\/e6a548c2c2596d8d63277db7af714bab","name":"Nolan Sroczynski","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.kff.org\/#\/schema\/person\/image\/","url":"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2022\/12\/Sroczynski-Nolan.jpg?w=300","contentUrl":"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2022\/12\/Sroczynski-Nolan.jpg?w=300","caption":"Nolan Sroczynski"},"url":"https:\/\/www.kff.org\/person\/nolan-sroczynski\/"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2026\/02\/The-IRA-Coverage-Requirement-for-Selected-Drugs-Will-Improve-Access-to-the-GLP-1-Drug-Wegovy-and-Six-Other-Part-D-Drugs-Selected-for-Negotiation-in-Round-2-Starting-in-2027_FI.png","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/pgulFb-2WT4","jetpack-related-posts":[{"id":691066,"url":"https:\/\/www.kff.org\/medicare\/people-with-medicare-will-face-higher-costs-for-some-orphan-drugs-due-to-changes-in-the-new-tax-and-budget-law\/","url_meta":{"origin":703022,"position":0},"title":"People with Medicare Will Face Higher Costs for Some Orphan Drugs Due to Changes in the New Tax and Budget Law","author":"kffjuliettec","date":"Oct 20, 2025","format":false,"excerpt":"This brief analyzes changes in the new tax and budget reconciliation law that modify which drugs will be selected for Medicare drug price negotiation, which will lead to higher Medicare spending and higher costs for beneficiaries who take these medications.","rel":"","context":"In &quot;Medicare&quot;","block_context":{"text":"Medicare","link":"https:\/\/www.kff.org\/topic\/medicare\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2025\/09\/Medicare-orphan-drugs-and-2025-tax-and-spend-law_FI.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2025\/09\/Medicare-orphan-drugs-and-2025-tax-and-spend-law_FI.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2025\/09\/Medicare-orphan-drugs-and-2025-tax-and-spend-law_FI.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2025\/09\/Medicare-orphan-drugs-and-2025-tax-and-spend-law_FI.png?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":611468,"url":"https:\/\/www.kff.org\/medicare\/3-charts-about-medicare-drug-price-negotiations\/","url_meta":{"origin":703022,"position":1},"title":"3 Charts: Medicare Drug Price Negotiations","author":"kffrainl","date":"Jan 31, 2024","format":false,"excerpt":"Under the Inflation Reduction Act, the federal government for the first time will negotiate directly with drug companies to determine the prices that Medicare will pay for certain high expenditure drugs covered under Medicare Part D (starting in 2026) and Part B (starting in 2028). Part D covers retail prescription\u2026","rel":"","context":"In &quot;Affordable Care Act&quot;","block_context":{"text":"Affordable Care Act","link":"https:\/\/www.kff.org\/topic\/affordable-care-act\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2023\/11\/kff-news-release-4-2.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2023\/11\/kff-news-release-4-2.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2023\/11\/kff-news-release-4-2.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2023\/11\/kff-news-release-4-2.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":659995,"url":"https:\/\/www.kff.org\/medicare\/the-effect-of-delaying-the-selection-of-small-molecule-drugs-for-medicare-drug-price-negotiation\/","url_meta":{"origin":703022,"position":2},"title":"The Effect of Delaying the Selection of Small Molecule Drugs for Medicare Drug Price Negotiation","author":"kffjuliettec","date":"Apr 16, 2025","format":false,"excerpt":"In a new Trump administration executive order, the Secretary of HHS is directed to work with Congress to implement a change in law to delay negotiation of so-called \u201csmall molecule\u201d drugs under the Inflation Reduction Act's Medicare Drug Price Negotiation Program for an additional 4 years. This brief analyzes how\u2026","rel":"","context":"In &quot;Health Costs&quot;","block_context":{"text":"Health Costs","link":"https:\/\/www.kff.org\/topic\/health-costs\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2025\/04\/FEATURE-Medicare-EO-Small-Molecule-Drugs.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2025\/04\/FEATURE-Medicare-EO-Small-Molecule-Drugs.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2025\/04\/FEATURE-Medicare-EO-Small-Molecule-Drugs.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2025\/04\/FEATURE-Medicare-EO-Small-Molecule-Drugs.png?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":592683,"url":"https:\/\/www.kff.org\/medicare\/a-small-number-of-drugs-account-for-a-large-share-of-medicare-part-d-spending\/","url_meta":{"origin":703022,"position":3},"title":"A Small Number of Drugs Account for a Large Share of Medicare Part D Spending","author":"kffjuliettec","date":"Jul 12, 2023","format":false,"excerpt":"The Inflation Reduction Act requires the federal government to negotiate the price of certain high-spending drugs covered by Medicare. This analysis provides context for understanding the potential impact of negotiating prices for a limited number of Medicare-covered drugs by identifying the 10 top-selling Part D drugs in 2021, measuring the\u2026","rel":"","context":"In &quot;Medicare&quot;","block_context":{"text":"Medicare","link":"https:\/\/www.kff.org\/topic\/medicare\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2023\/07\/total-gross-spending-on-the-top-10-medicare-part-d-drugs-in-2021-ranged-from-2.6-billion-for-ozempic-a-diabetes-drug-to-12.6-billion-for-eliquis-a-blood-thinner.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2023\/07\/total-gross-spending-on-the-top-10-medicare-part-d-drugs-in-2021-ranged-from-2.6-billion-for-ozempic-a-diabetes-drug-to-12.6-billion-for-eliquis-a-blood-thinner.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2023\/07\/total-gross-spending-on-the-top-10-medicare-part-d-drugs-in-2021-ranged-from-2.6-billion-for-ozempic-a-diabetes-drug-to-12.6-billion-for-eliquis-a-blood-thinner.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2023\/07\/total-gross-spending-on-the-top-10-medicare-part-d-drugs-in-2021-ranged-from-2.6-billion-for-ozempic-a-diabetes-drug-to-12.6-billion-for-eliquis-a-blood-thinner.png?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":534751,"url":"https:\/\/www.kff.org\/medicare\/drug-price-negotiation-doesnt-mean-the-government-will-restrict-access-to-medicines\/","url_meta":{"origin":703022,"position":4},"title":"Drug Price Negotiation Doesn\u2019t Mean the Government Will Restrict Access to Medicines","author":"kffjuliettec","date":"Oct 7, 2021","format":false,"excerpt":"This policy watch evaluates the pharmaceutical industry's claims that allowing the federal government to negotiate drug prices would restrict access to medications in Medicare. It explains what the current proposal to allow drug price negotiation would and wouldn't do.","rel":"","context":"In &quot;Medicare&quot;","block_context":{"text":"Medicare","link":"https:\/\/www.kff.org\/topic\/medicare\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2021\/10\/DrugPriceNegotiationFeatureImagePolicyWatch-1.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2021\/10\/DrugPriceNegotiationFeatureImagePolicyWatch-1.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2021\/10\/DrugPriceNegotiationFeatureImagePolicyWatch-1.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2021\/10\/DrugPriceNegotiationFeatureImagePolicyWatch-1.png?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":545481,"url":"https:\/\/www.kff.org\/medicare\/millions-of-medicare-beneficiaries-use-prescription-drugs-that-could-be-subject-to-price-negotiation-but-build-back-better-act-provision-exempts-many-drugs-with-high-federal-spending\/","url_meta":{"origin":703022,"position":5},"title":"Millions of Medicare Beneficiaries Use Prescription Drugs That Could Be Subject to Price Negotiation, But Build Back Better Act Provision Exempts Many Drugs With High Federal Spending","author":"kfftiffanyf","date":"Jan 27, 2022","format":false,"excerpt":"Twenty drugs and dozens of insulin products used by 8.5 million Medicare beneficiaries would be subject to government drug price negotiation if the Build Back Better Act (BBBA) were enacted and fully implemented in 2022, according to a new KFF analysis. The 20 drugs include 18 drugs available to beneficiaries\u2026","rel":"","context":"In &quot;Medicare&quot;","block_context":{"text":"Medicare","link":"https:\/\/www.kff.org\/topic\/medicare\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2020\/10\/FEATURE-News-Release_1.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2020\/10\/FEATURE-News-Release_1.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2020\/10\/FEATURE-News-Release_1.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2020\/10\/FEATURE-News-Release_1.png?resize=700%2C400&ssl=1 2x"},"classes":[]}],"primary_topic":"Medicare","publishpress_future_action":{"enabled":false,"date":"2026-02-23 07:25:47","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"distributor_meta":false,"distributor_terms":false,"distributor_media":false,"distributor_original_site_name":"KFF","distributor_original_site_url":"https:\/\/www.kff.org","push-errors":false,"_links":{"self":[{"href":"https:\/\/www.kff.org\/wp-json\/wp\/v2\/posts\/703022","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.kff.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.kff.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.kff.org\/wp-json\/wp\/v2\/users\/48717755"}],"replies":[{"embeddable":true,"href":"https:\/\/www.kff.org\/wp-json\/wp\/v2\/comments?post=703022"}],"version-history":[{"count":4,"href":"https:\/\/www.kff.org\/wp-json\/wp\/v2\/posts\/703022\/revisions"}],"predecessor-version":[{"id":703052,"href":"https:\/\/www.kff.org\/wp-json\/wp\/v2\/posts\/703022\/revisions\/703052"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.kff.org\/wp-json\/wp\/v2\/media\/703065"}],"wp:attachment":[{"href":"https:\/\/www.kff.org\/wp-json\/wp\/v2\/media?parent=703022"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.kff.org\/wp-json\/wp\/v2\/categories?post=703022"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.kff.org\/wp-json\/wp\/v2\/tags?post=703022"},{"taxonomy":"content-types","embeddable":true,"href":"https:\/\/www.kff.org\/wp-json\/wp\/v2\/content-types?post=703022"},{"taxonomy":"series","embeddable":true,"href":"https:\/\/www.kff.org\/wp-json\/wp\/v2\/series?post=703022"},{"taxonomy":"program","embeddable":true,"href":"https:\/\/www.kff.org\/wp-json\/wp\/v2\/program?post=703022"},{"taxonomy":"partner","embeddable":true,"href":"https:\/\/www.kff.org\/wp-json\/wp\/v2\/partner?post=703022"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}